Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib

Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). To characterise the relative safety profile of tofacitinib to biologic disease-modifying antirheumatic drugs (bDMARDs), the accrued patient-years (pt-yrs) of exposure needed in an RA clinical trial programm...

Descripción completa

Detalles Bibliográficos
Autores principales: Curtis, Jeffrey R., Zhang, Richard, Krishnaswami, Sriram, Anisfeld, Andrew, Chen, Yan, Strengholt, Sander, Chen, Connie, Geier, Jamie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2016
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323490/
https://www.ncbi.nlm.nih.gov/pubmed/27470086
http://dx.doi.org/10.1007/s10067-016-3359-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323490/
https://www.ncbi.nlm.nih.gov/pubmed/27470086
http://dx.doi.org/10.1007/s10067-016-3359-x

Ejemplares similares